One-year outcomes in cardiogenic shock triggered by ventricular arrhythmia: An analysis of the FRENSHOCK multicenter prospective registry.
cardiogenic shock
epidemiology
prognosis
ventricular arrhythmia
ventricular tachycardia
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
11
2022
accepted:
09
01
2023
entrez:
13
2
2023
pubmed:
14
2
2023
medline:
14
2
2023
Statut:
epublish
Résumé
Cardiogenic shock (CS) is a life-threatening condition carrying poor prognosis, potentially triggered by ventricular arrhythmia (VA). Whether the occurrence of VA as trigger of CS worsens the prognosis compared to non-VA triggers remains unclear. The aim of this study was to evaluate 1-year outcomes [mortality, heart transplantation, ventricular assist devices (VAD)] between VA-triggered and non-VA-triggered CS. FRENSHOCK is a prospective multicenter registry including 772 CS patients from 49 centers. One to three triggers can be identified in the registry (ischemic, mechanical complications, ventricular/supraventricular arrhythmia, bradycardia, iatrogenesis, infection, non-compliance). Baseline characteristics, management and 1-year outcomes were analyzed according to the VA-trigger in the CS population. Within 769 CS patients included, 94 were VA-triggered (12.2%) and were compared to others. At 1 year, although there was no mortality difference [42.6 vs. 45.3%, HR 0.94 (0.67-1.30), VA-triggered CS did not show higher mortality compared to other triggers but resulted in more heart transplantation and VAD at 1 year, especially in non-ischemic cardiomyopathy, suggesting the need for earlier evaluation by advanced heart failure specialized team for a possible indication of mechanical circulatory support or heart transplantation. https://clinicaltrials.gov, identifier NCT02703038.
Sections du résumé
Background
UNASSIGNED
Cardiogenic shock (CS) is a life-threatening condition carrying poor prognosis, potentially triggered by ventricular arrhythmia (VA). Whether the occurrence of VA as trigger of CS worsens the prognosis compared to non-VA triggers remains unclear. The aim of this study was to evaluate 1-year outcomes [mortality, heart transplantation, ventricular assist devices (VAD)] between VA-triggered and non-VA-triggered CS.
Methods
UNASSIGNED
FRENSHOCK is a prospective multicenter registry including 772 CS patients from 49 centers. One to three triggers can be identified in the registry (ischemic, mechanical complications, ventricular/supraventricular arrhythmia, bradycardia, iatrogenesis, infection, non-compliance). Baseline characteristics, management and 1-year outcomes were analyzed according to the VA-trigger in the CS population.
Results
UNASSIGNED
Within 769 CS patients included, 94 were VA-triggered (12.2%) and were compared to others. At 1 year, although there was no mortality difference [42.6 vs. 45.3%, HR 0.94 (0.67-1.30),
Conclusion
UNASSIGNED
VA-triggered CS did not show higher mortality compared to other triggers but resulted in more heart transplantation and VAD at 1 year, especially in non-ischemic cardiomyopathy, suggesting the need for earlier evaluation by advanced heart failure specialized team for a possible indication of mechanical circulatory support or heart transplantation.
Clinical trial registration
UNASSIGNED
https://clinicaltrials.gov, identifier NCT02703038.
Identifiants
pubmed: 36776263
doi: 10.3389/fcvm.2023.1092904
pmc: PMC9909601
doi:
Banques de données
ClinicalTrials.gov
['NCT02703038']
Types de publication
Journal Article
Langues
eng
Pagination
1092904Informations de copyright
Copyright © 2023 Cherbi, Roubille, Lamblin, Bonello, Leurent, Levy, Elbaz, Champion, Lim, Schneider, Cariou, Khachab, Bourenne, Seronde, Schurtz, Harbaoui, Vanzetto, Quentin, Delabranche, Aissaoui, Combaret, Tomasevic, Marchandot, Lattuca, Henry, Gerbaud, Bonnefoy, Puymirat, Maury and Delmas.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Coll Cardiol. 2022 Sep 13;80(11):1045-1056
pubmed: 36075673
Eur J Heart Fail. 2015 May;17(5):501-9
pubmed: 25820680
Circulation. 2022 Jun 21;145(25):1839-1849
pubmed: 35507499
Arch Cardiovasc Dis. 2019 Dec;112(12):738-747
pubmed: 31155464
J Clin Med. 2020 Mar 28;9(4):
pubmed: 32231121
Circ Cardiovasc Qual Outcomes. 2019 Mar;12(3):e005618
pubmed: 30879324
Am J Cardiol. 2020 Jun 15;125(12):1774-1781
pubmed: 32307093
Can J Cardiol. 2022 Apr;38(4):454-464
pubmed: 35074416
N Engl J Med. 2016 Jul 14;375(2):111-21
pubmed: 27149033
J Am Coll Cardiol. 2013 Oct 29;62(18):1674-1679
pubmed: 23810882
Europace. 2019 Aug 1;21(8):1143-1144
pubmed: 31075787
Heart Rhythm. 2018 Jan;15(1):48-55
pubmed: 28843418
ESC Heart Fail. 2022 Feb;9(1):408-419
pubmed: 34973047
Eur Heart J. 2015 May 21;36(20):1223-30
pubmed: 25732762
JAMA Cardiol. 2019 Sep 1;4(9):928-935
pubmed: 31339509
Catheter Cardiovasc Interv. 2019 Jul 1;94(1):29-37
pubmed: 31104355
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Circulation. 2008 Jan 29;117(4):462-9
pubmed: 18172038
Arch Cardiovasc Dis. 2019 May;112(5):343-353
pubmed: 30982720
J Card Fail. 2021 Oct;27(10):1082-1089
pubmed: 34625128
J Am Heart Assoc. 2019 Apr 16;8(8):e011991
pubmed: 30947630
JACC Clin Electrophysiol. 2022 Jan;8(1):1-11
pubmed: 34454875
Crit Care. 2014 Sep 19;18(5):516
pubmed: 25246084
Circulation. 2022 Jun 21;145(25):1829-1838
pubmed: 35369700
J Am Coll Cardiol. 2013 Oct 29;62(18):1680-1682
pubmed: 23810888
Arch Med Sci. 2019 Jul;15(4):845-856
pubmed: 31360179
Eur Heart J Acute Cardiovasc Care. 2022 Jun 14;11(5):431-439
pubmed: 35512138